Stay updated with breaking news from Ancer Immunotherapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Compugen Ltd. (NASDAQ:CGEN) Q2 2023 Earnings Call Transcript August 7, 2023 Operator: Ladies and gentlemen, thank you for joining us today. Welcome to Compugen’s Second Quarter 2023 Results Conference Call. At this time, all participants are in a listen-only mode. As a reminder, today’s call is being recorded. An audio webcast of this call will […]
Deep-learning technology developed by a team of Johns Hopkins engineers and cancer researchers can accurately predict cancer-related protein fragments that may trigger an immune system response.
T cells recognize and kill cancer cells but quickly lose their effectiveness. This fast dysfunction may help explain why immunotherapy doesn’t lead to long-term remission for many patients.
(Reuters) -Merck & Co posted better-than-expected second-quarter sales on Tuesday on strong demand for its two top-selling products, cancer immunotherapy Keytruda and human papillomavirus (HPV) vaccine Gardasil. Shares of Merck rose about 2% at $108.45 in premarket trading after the company also raised its full-year revenue forecast. Merck said Keytruda sales for the quarter jumped 19% to $6.3 billion, surpassing analysts' average estimate of $5.9 billion.
Dublin, July 21, 2023 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Markets. The Race for the Cures. Market Forecasts for Immuno-Oncology Therapeutics by...